Renoprotective effect of alprostadil in combination with statins in patients with mild to moderate renal failure undergoing coronary angiography

Chinese Medical Journal

Volumn 126, Issue 18, 2013, Pages 3475-3480

  Liu, Wei Jing ^a   Zhang, Bu Chun ^a   Guo, Rong ^a   Wei, Yi Dong ^a   Li, Wei Ming ^a   Xu, Ya Wei ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Alprostadil; Coronary angiography; Renal failure; Statins

Indexed keywords

ATORVASTATIN; CREATININE; CYSTATIN C; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IODIXANOL; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROSTAGLANDIN E1; ROSUVASTATIN; SIMVASTATIN;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; BRAIN ISCHEMIA; CONGESTIVE HEART FAILURE; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; DRUG TOLERANCE; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; TURBIDIMETRY;

ADOLESCENT; ADULT; AGED; ALPROSTADIL; CORONARY ANGIOGRAPHY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84884239689     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20123487     Document Type: Article

References (30)

1. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002; 39: 930-936.
2. Sudarsky D, Nikolsky E. Contrast-induced nephropathy in interventional cardiology. Int J Nephrol Renovasc Dis 2011; 4: 85-99.
3. Ozhan H, Erden I, Ordu S, Aydin M, Caglar O, Basar C, et al. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography Angiology 2010; 61: 711-714.
4. Acikel S, Muderrisoglu H, Yildirir A, Aydinalp A, Sade E, Bayraktar N, et al. Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography. Blood Coagul Fibrinolysis 2010; 21: 750-757.
5. Zhang BC, Li WM, Xu YW. High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis. Can J Cardiol 2011; 27: 851-858.
6. Koch JA, Plum J, Grabensee B, Mödder U. Prostaglandin E1: a new agent for renal dysfunction in high risk patients caused by radiocontrast media? Nephrol Dial Transplant 2000; 15: 43-49.
7. Bader BD, Berger ED, Heede MB, Silberbaur I, Duda S, Risler T, et al. What is the best hydration regimen to prevent contrast media-induced nephrotoxicity? Clin Nephrol 2004; 62: 1-7.
8. Senoo T, Motohiro M, Kamihata H, Yamamoto S, Isono T, Manabe K, et al. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome. Am J Cardiol 2010; 105: 624-628.
9. Evans RG, Gardiner BS, Smith DW, O'Connor PM. Intrarenal oxygenation: unique challenges and the biophysical basis of homeostasis. Am J Physiol Renal Physiol 2008; 295: F1259-F1270.
10. Haase J, Escaned J, van Swijndregt EM, Ozaki Y, Gronenschild E, Slager CJ, et al. Experimental validation of geometric and densitometric coronary measurements on the new generation Cardiovascular Angiography Analysis System (CAAS II). Cathet Cardiovasc Diagn 1993; 30: 104-114.
11. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med 1985; 312: 932-936.
12. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008; 51: 1419-1428.
13. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996; 275: 1489-1494.
14. Solomon RJ, Mehran R, Natarajan MK, Doucet S, Katholi RE, Staniloae CS, et al. Contrast-induced nephropathy and long-term adverse events: cause and effect? Clin J Am Soc Nephrol 2009; 4: 1162-1169.
15. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W, et al. Prevention of radiographic contrast agent induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343: 180-184.
16. Neumayer HH, Junge W, Küfner A, Wenning A. Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial. Nephrol Dial Transplant 1989; 4: 1030-1036.
17. Hoffmann U, Fischereder M, Krüger B, Drobnik W, Krämer BK. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004; 15: 407-410.
18. Jo SH, Koo BK, Park JS, Kang HJ, Cho YS, Kim YJ. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial-a randomized controlled study. Am Heart J 2008; 17: 616-623.
19. Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 2005; 95: 13-19.
20. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J 2003; 24: 225-248.
21. Tuo Z, Ling-Hong S, Liu-Hua H, Ben H. Statins for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Nephrol 2011; 33: 344-351.
22. Wu CC, Wu CI, Wang WY, Wu YC. Low concentrations of resveratrol potentiate the antiplatelet effect of prostaglandins. Planta Medica 2007; 73: 439-443.
23. Dolegowska B, Pikual E, Safranow K, Olszewska M, Jakubowska K, Chlubek D, et al. Metabolism of eicosanoids and their action on renal function during ischaemia and reperfusion: the effect of alprostadil. Prostaglandins Leukot Essent Fatty Acids 2006; 75: 403-411.
24. Brinker JA, Sketch M, Koch JA, Bernink P. PGE1 prophylaxis against contrast-induced nephropathy in patients with pre-existent renal compromise: results of a randomized, controlled pilot trial. Circulation 1998; 98: 707A.
25. Kellum JA, Levin N, Bouman C, Lameire N. Developing a consensus classification for acute renal failure. Curr Opin Crit Care 2002; 8: 509-514.
26. Bellomo R, Kellum JA, Ronco C. Defining acute renal physiological principles. Intensive Care Med 2004; 30: 33-37.
27. Tenstad O, Roald AB, Grubb A, Aukland K. Renal handling of radiolabelled human cystatin C in the rat. Scand J Clin Lab Invest 1996; 56: 409-414.
28. Mussap M, DallaVestra M, Fioretto P, Saller A, Varagnolo M, Nosadini R, et al. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int 2002; 61: 1453-1461.
29. Mishra J, Mori K, Ma Q, Kelly C, Yang J, Mitsnefes M, et al. Amelioration of ischemic acute renal injury by NGAL. J Am Soc Nephrol 2004; 15: 3073-3082.
30. Ling W, Zhaohui N, Ben H, Leyi G, Jianping L, Huili D, et al. Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography. Nephron Clin Pract 2008; 108: 176-181.